Table 2. Change from baseline in hospital anxiety and depression scale scores and visual analog scale scores at the recall visit for patients treated with poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy in a clinical study [20]

 

	Immediate Group (n=13)		Delayed Group (n=14)
	Baseline	Recall Visit	Baseline	Recall Visit
Anxiety score	7.9	7.2	10.3	7.9
Depression score	5.1	4.8	7.3	3.8
Visual analog scale score*	2.5	5.8	1.4	5.5

*P<0.05 between groups for mean change from baseline at recall visit (paired test).

 

Adapted with permission from Moyle GJ et al, Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy, HIV Med. 2006; 7:181-185 [20].